BRIEF published on 11/13/2025 at 10:12, 21 days 18 hours ago Biotest Obtains Approval for Prufibry® in Germany Clinical Trials Biotest AG German Market Prufibry® Approval Fibrinogen Deficiency
PRESS RELEASE published on 11/13/2025 at 10:07, 21 days 18 hours ago Biotest obtains approval for new human fibrinogen Prufibry® in Germany Biotest AG obtains approval in Germany for new human fibrinogen Prufibry®, expanding intensive care and coagulation factor portfolio with a life-saving therapy for congenital and acquired fibrinogen deficiency Germany Biotest AG Approval Human Fibrinogen Prufibry
BRIEF published on 11/07/2025 at 15:24, 27 days 13 hours ago Biotest AG Schedules Extraordinary General Meeting at Grifols' Request Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 11/07/2025 at 15:19, 27 days 13 hours ago Biotest AG: Extraordinary general meeting convened again at the request of Grifols S.A. Biotest AG convenes an extraordinary general meeting at the request of Grifols S.A. to discuss changing its legal form to a partnership limited by shares (KGaA) on 17 December 2025 Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
BRIEF published on 10/23/2025 at 13:21, 1 month 12 days ago Biotest AG Cancels Extraordinary General Meeting Grifols S.A. Extraordinary General Meeting Legal Form Change Corporate Restructuring Biotest AG News
PRESS RELEASE published on 10/23/2025 at 13:16, 1 month 12 days ago Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025 Biotest AG cancels extraordinary general meeting scheduled for 28 October 2025 following withdrawal of convocation request by Grifols S.A Grifols S.A. Cancellation Extraordinary General Meeting Biotest AG Legal Form Change
BRIEF published on 10/09/2025 at 17:35, 1 month 26 days ago Biotest's Yimmugo® Enters the U.S. Market Biotest AG U.S. Market Yimmugo® Launch Primary Immunodeficiencies Plasma-derived Medicines
PRESS RELEASE published on 10/09/2025 at 17:30, 1 month 26 days ago Biotest’s Yimmugo® launches in the United States Biotest AG launches Yimmugo®, a polyvalent human normal immunoglobulin (IVIg) for primary immunodeficiencies in the U.S., marking a significant milestone for the company's global growth strategy Biotest AG Yimmugo U.S. Launch Primary Immunodeficiencies IVIg
BRIEF published on 09/19/2025 at 15:05, 2 months 15 days ago Biotest AG Schedules Extraordinary General Meeting for Legal Form Change Grifols S.A. Extraordinary General Meeting Biotest AG Legal Form Change Partnership Limited By Shares
PRESS RELEASE published on 09/19/2025 at 15:00, 2 months 15 days ago Biotest AG: Extraordinary general meeting convened at the request of Grifols S.A. Biotest AG's extraordinary general meeting convened at the request of Grifols S.A. to discuss changing legal form to a partnership limited by shares (KGaA) on 28 October 2025 Extraordinary General Meeting Biotest AG Legal Form Change Grifols Partnership Limited By Shares
Published on 12/05/2025 at 02:35, 1 hour 57 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 3 hours 32 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 5 hours 27 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 5 hours 32 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 1 hour 2 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 4 hours 41 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 8 hours 7 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 8 hours 17 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 9 hours 21 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:00, 10 hours 32 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 10 hours 47 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 10 hours 48 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 21 hours 31 minutes ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 10 hours ago Declaration of voting rights at the end of November 2025
